ENGLEWOOD, Colo., July 22, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, will hold a conference call on Thursday, July 31, 2025 at 4:15 PM Eastern Time to discuss its financial results for the second quarter ended June 30, 2025.  Financial results will be issued in a press release prior to the call.Zynex management will host the con ...

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company has a team of experienced and qualified news journalists who produce independent content [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The news team delivers insights across various sectors including biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for its forward-looking approach and enthusiastic adoption of technology to enhance workflows [4] - The company utilizes automation and software tools, including generative AI, while ensuring that all content is edited and authored by humans [5]

Company Overview - Zynex, Inc. is an innovative medical technology company focused on noninvasive medical devices for pain management, rehabilitation, and patient monitoring [1][10] - The company has been awarded UK patent 2617515 for a multiparameter, noninvasive sepsis monitor [1] Industry Context - Sepsis is a critical global health issue, with over 1.7 million cases annually in the United States and a mortality rate that is among the highest for medical conditions [2][3] - Globally, sepsis results in approximately 11 million deaths each year, accounting for about 20% of total deaths, with a significant portion of cases occurring in children under 5 years old [2][3] Product Development - Zynex aims to develop a noninvasive, highly accurate sepsis monitor that continuously tracks multiple physiological signals to provide real-time alerts to clinicians [3][4] - The device is expected to enhance early detection and treatment of sepsis, potentially reducing mortality rates associated with this condition [4]